Goldman cuts BioArctic on valuation, competitive risks from Eli Lilly; shares down

Investing.com Gold reports: Goldman cuts BioArctic on valuation, competitive risks from Eli Lilly; shares down. Full body text was unavailable at ingest time, so this brief is based on headline context.